Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the ...

Study compares effectiveness of popular weight loss drugs 02:38. Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.

In a head-to-head study in the New England Journal of Medicine, people taking Zepbound, Wegovy, Zepbound led to greater weight loss.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said.

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time ...

Weight loss with Zepbound was not affected by age, sex, race, ethnicity, starting BMI, or blood sugar levels. The SURMOUNT-1 study compared three different doses of Zepbound (5 milligrams, 10 ...

The active ingredient in Eli Lilly's Mounjaro and Zepbound leads to more weight loss than the active ingredient in Novo Nordisk's Ozempic and Wegovy, according to a study published.